Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Eckermann

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Applied Health Economics and Health Policy|November 3, 2014
Kinky thresholds revisited: opportunity costs differ in the NE and SW quadrantsSimon Eckermann
Frontiers in Public Health|December 30, 2022
Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemicsSimon Eckermann
Frontiers in Public Health|March 21, 2024
Aligning opportunity cost and net benefit criteria: the health shadow priceSimon Eckermann
Social Science & Medicine (1982)|November 17, 2012
Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practiceSimon Eckermann, Tim Coelli
Pharmacoeconomics|February 12, 2014
Can the real opportunity cost stand up: displaced services, the straw man outside the roomSimon Eckermann, Brita Pekarsky
Health Economics|April 29, 2009
Optimal clinical trial design using value of information methods with imperfect implementationAndrew R Willan, Simon Eckermann
Pharmacoeconomics|May 18, 2012
Value of information and pricing new healthcare interventionsAndrew R Willan, Simon Eckermann
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 16, 2008
The option value of delay in health technology assessmentSimon Eckermann, Andrew R Willan
Health Economics|September 19, 2006
Expected value of information and decision making in HTASimon Eckermann, Andrew R Willan
Pharmacoeconomics|March 27, 2013
Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharingSimon Eckermann, Andrew R Willan
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Applied Health Economics and Health Policy|November 3, 2014
Kinky thresholds revisited: opportunity costs differ in the NE and SW quadrantsSimon Eckermann
Frontiers in Public Health|December 30, 2022
Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemicsSimon Eckermann
Frontiers in Public Health|March 21, 2024
Aligning opportunity cost and net benefit criteria: the health shadow priceSimon Eckermann
Social Science & Medicine (1982)|November 17, 2012
Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practiceSimon Eckermann, Tim Coelli
Pharmacoeconomics|February 12, 2014
Can the real opportunity cost stand up: displaced services, the straw man outside the roomSimon Eckermann, Brita Pekarsky
Health Economics|April 29, 2009
Optimal clinical trial design using value of information methods with imperfect implementationAndrew R Willan, Simon Eckermann
Pharmacoeconomics|May 18, 2012
Value of information and pricing new healthcare interventionsAndrew R Willan, Simon Eckermann
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 16, 2008
The option value of delay in health technology assessmentSimon Eckermann, Andrew R Willan
Health Economics|September 19, 2006
Expected value of information and decision making in HTASimon Eckermann, Andrew R Willan
Pharmacoeconomics|March 27, 2013
Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharingSimon Eckermann, Andrew R Willan
Pageof 6